FI95752B - Bestämningskitt och -förfarande för immunologisk mätning av hela celler - Google Patents
Bestämningskitt och -förfarande för immunologisk mätning av hela celler Download PDFInfo
- Publication number
- FI95752B FI95752B FI884472A FI884472A FI95752B FI 95752 B FI95752 B FI 95752B FI 884472 A FI884472 A FI 884472A FI 884472 A FI884472 A FI 884472A FI 95752 B FI95752 B FI 95752B
- Authority
- FI
- Finland
- Prior art keywords
- cells
- antigen
- antigens
- lymphocytes
- assay
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 115
- 230000001900 immune effect Effects 0.000 title claims description 15
- 238000005259 measurement Methods 0.000 title claims description 14
- 210000004027 cell Anatomy 0.000 claims abstract description 193
- 239000000427 antigen Substances 0.000 claims abstract description 161
- 102000036639 antigens Human genes 0.000 claims abstract description 159
- 108091007433 antigens Proteins 0.000 claims abstract description 159
- 238000003556 assay Methods 0.000 claims abstract description 58
- 102000004190 Enzymes Human genes 0.000 claims abstract description 41
- 108090000790 Enzymes Proteins 0.000 claims abstract description 41
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 41
- 239000007787 solid Substances 0.000 claims abstract description 34
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 32
- 238000003149 assay kit Methods 0.000 claims abstract description 15
- 230000000694 effects Effects 0.000 claims abstract description 14
- 239000000758 substrate Substances 0.000 claims abstract description 14
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 claims abstract description 13
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 claims abstract description 12
- 238000001179 sorption measurement Methods 0.000 claims abstract description 6
- 229940088598 enzyme Drugs 0.000 claims description 38
- 239000000243 solution Substances 0.000 claims description 35
- 210000004369 blood Anatomy 0.000 claims description 34
- 239000008280 blood Substances 0.000 claims description 34
- 108040007629 peroxidase activity proteins Proteins 0.000 claims description 30
- 210000004698 lymphocyte Anatomy 0.000 claims description 17
- 229940044173 iodine-125 Drugs 0.000 claims description 14
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 13
- 230000002255 enzymatic effect Effects 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 210000004881 tumor cell Anatomy 0.000 claims description 13
- 210000003714 granulocyte Anatomy 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 108010022752 Acetylcholinesterase Proteins 0.000 claims description 10
- 229940022698 acetylcholinesterase Drugs 0.000 claims description 10
- 210000001772 blood platelet Anatomy 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 10
- 239000003550 marker Substances 0.000 claims description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 claims description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 claims description 9
- 210000000265 leukocyte Anatomy 0.000 claims description 9
- 230000003211 malignant effect Effects 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 7
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 6
- 229940095731 candida albicans Drugs 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 6
- 241000222122 Candida albicans Species 0.000 claims description 5
- 230000000890 antigenic effect Effects 0.000 claims description 5
- 244000000010 microbial pathogen Species 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 claims description 4
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 claims description 4
- 208000006593 Urologic Neoplasms Diseases 0.000 claims description 4
- 230000003100 immobilizing effect Effects 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 claims description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims description 3
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 claims description 3
- 102000003992 Peroxidases Human genes 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 210000001822 immobilized cell Anatomy 0.000 claims description 3
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 claims description 2
- OXEUETBFKVCRNP-UHFFFAOYSA-N 9-ethyl-3-carbazolamine Chemical compound NC1=CC=C2N(CC)C3=CC=CC=C3C2=C1 OXEUETBFKVCRNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000011534 wash buffer Substances 0.000 claims description 2
- PSGQCCSGKGJLRL-UHFFFAOYSA-N 4-methyl-2h-chromen-2-one Chemical group C1=CC=CC2=C1OC(=O)C=C2C PSGQCCSGKGJLRL-UHFFFAOYSA-N 0.000 claims 2
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 2
- 102000005936 beta-Galactosidase Human genes 0.000 claims 2
- ZCYVEMRRCGMTRW-YPZZEJLDSA-N iodine-125 Chemical compound [125I] ZCYVEMRRCGMTRW-YPZZEJLDSA-N 0.000 claims 2
- 101710084021 Large envelope protein Proteins 0.000 claims 1
- 210000000649 b-lymphocyte subset Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910021653 sulphate ion Inorganic materials 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 239000000523 sample Substances 0.000 abstract 3
- 238000013198 immunometric assay Methods 0.000 abstract 1
- 239000002953 phosphate buffered saline Substances 0.000 description 29
- 102000013415 peroxidase activity proteins Human genes 0.000 description 28
- 238000002372 labelling Methods 0.000 description 24
- 238000012360 testing method Methods 0.000 description 23
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 22
- 239000000872 buffer Substances 0.000 description 21
- 230000003287 optical effect Effects 0.000 description 21
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 20
- 210000005087 mononuclear cell Anatomy 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 13
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 12
- 238000003312 immunocapture Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000011324 bead Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 102100033639 Acetylcholinesterase Human genes 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 208000032839 leukemia Diseases 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 108010041397 CD4 Antigens Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 238000005119 centrifugation Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 6
- 230000002285 radioactive effect Effects 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000007795 chemical reaction product Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 229940127121 immunoconjugate Drugs 0.000 description 5
- 102100026189 Beta-galactosidase Human genes 0.000 description 4
- 102000006354 HLA-DR Antigens Human genes 0.000 description 4
- 108010058597 HLA-DR Antigens Proteins 0.000 description 4
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000007430 reference method Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 description 3
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 3
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 description 3
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 3
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 3
- 102000003729 Neprilysin Human genes 0.000 description 3
- 108090000028 Neprilysin Proteins 0.000 description 3
- 108010047620 Phytohemagglutinins Proteins 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000000601 blood cell Anatomy 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000007444 cell Immobilization Methods 0.000 description 3
- 239000007979 citrate buffer Substances 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 230000002380 cytological effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 239000012997 ficoll-paque Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007850 fluorescent dye Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000003018 immunoassay Methods 0.000 description 3
- 238000010166 immunofluorescence Methods 0.000 description 3
- 238000010324 immunological assay Methods 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000001885 phytohemagglutinin Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 241000189662 Calla Species 0.000 description 2
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 108010029157 Sialic Acid Binding Ig-like Lectin 2 Proteins 0.000 description 2
- 108010077673 Tetraspanin 29 Proteins 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 208000026278 immune system disease Diseases 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- ZAFUNKXZZPSTLA-MBKDEEHCSA-N n-[(2r,3r,4r,5r)-5,6-dihydroxy-1-oxo-4-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2s,3s,4r,5s,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}hexan-2-yl]acetamide Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](NC(C)=O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 ZAFUNKXZZPSTLA-MBKDEEHCSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 108010079983 plasmion Proteins 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- -1 rhodamine isothiocyanate Chemical class 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000002798 spectrophotometry method Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- BCHIXGBGRHLSBE-UHFFFAOYSA-N (4-methyl-2-oxochromen-7-yl) dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C=CC2=C1OC(=O)C=C2C BCHIXGBGRHLSBE-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100037904 CD9 antigen Human genes 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102100033040 Carbonic anhydrase 12 Human genes 0.000 description 1
- 102000003914 Cholinesterases Human genes 0.000 description 1
- 108090000322 Cholinesterases Proteins 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 108010062580 Concanavalin A Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101000801357 Electrophorus electricus Acetylcholinesterase Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000011786 HLA-A Antigens Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 description 1
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 description 1
- 101000867855 Homo sapiens Carbonic anhydrase 12 Proteins 0.000 description 1
- 101000934376 Homo sapiens T-cell differentiation antigen CD6 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010093096 Immobilized Enzymes Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 description 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 238000012773 Laboratory assay Methods 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108010013709 Leukocyte Common Antigens Proteins 0.000 description 1
- 102000017095 Leukocyte Common Antigens Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 101710171243 Peroxidase 10 Proteins 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 102000001613 Sialic Acid Binding Ig-like Lectin 2 Human genes 0.000 description 1
- 102100025131 T-cell differentiation antigen CD6 Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 102000010431 Tetraspanin 29 Human genes 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001032 anti-candidal effect Effects 0.000 description 1
- 230000002022 anti-cellular effect Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 229940048961 cholinesterase Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 229960002303 citric acid monohydrate Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000002794 lymphocyte assay Methods 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 210000003593 megakaryocyte Anatomy 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001167 myeloblast Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000029584 urinary system neoplasm Diseases 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/544—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being organic
- G01N33/545—Synthetic resin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (37)
1. Bestämningskitt för immunologisk bestämning av en för en cellpopulation eller des s undergrupp specifik 5 ytantigen, kännetecknat av att den har följan-de komponenter: a) en fast bärare, pä vilken medelst kovalent bind-ning eller fysikalisk adsorption fästs en eller flera mo-noklonala antikroppar mot nägon annan antigen än nämnda 10 typiska ytantigen hos cellpopulationen som skall mätäs; b) en eller flera lösningar, av vilka var och en innehäller en för den cellpopulation som skall mätäs eller en undergrupp av densamma specifik monoklonal antigen, som är märkt med ett radioaktivt eller enzymatiskt märke; 15 c) i det fall att antikroppen är märkt med ett en- zym, en eller flera lösningar, som innehäller erforderliga reagenser för pävisning av enzymets aktivitet; d) en eventuell tilläggskomponent, som bestär av en tvättbuffert och/eller prov, med hjälp av vilka mätningens 20 kvalitet kan jämföras och kontrolleras.
2. Kitt enligt patentkrav 1, kännetecknat av att komponenten (a) är en fast bärare, som är en mikrotiterplatta, i vars häl antikroppen eller -kropparna är fästa, vilka är avsedda att immobilisera de celler . 25 bland cellpopulationerna eller undergrupperna som innehäl- ler antigenen som skall bestämmas.
3. Kitt enligt patentkrav 1, kännetecknat av att komponenten (a) är en speciell magnetisk bärare.
4. Kitt enligt nägot av patentkraven 1-3, k ä n - ,, netecknatav att komponenten (a) är en fast bära re, pä vilken en eller flera monoklonala antikroppar mot HLA-klass 1 fästs.
5. Kitt enligt nägot av patentkraven 1-3, k ä n - 35 netecknatav att de monoklonala antikropparna i 11 95752 komponenten (b) är märkta med ett radioisotopmärke som är jod-125 eller jod-131.
6. Kitt enligt nägot av patentkraven 1-3, k ä n -netecknat av att de monoklonala antikropparna i 5 komponenten (b) är märkta med ett enzymmärke.
7. Kitt enligt patentkrav 6, känneteck-n a t av att de monoklonala antikropparna i komponenten (b) är märkta med peroxidas, och komponenten (c) innehäl-ler absolut oxiderat vatten och en kromogen, som är orto- 10 fenylendiamin, 2,2'-azino-bis-(3-etylbensotiazolin-6- sulfon)syra, 3,3'-diaminobensidin, 3-amino-9-etylkarbazol eller ett vattenlösligt sait av dessa.
8. Kitt enligt patentkrav 6, känneteck-n a t av att den monoklonala antikroppen i komponenten 15 (b) är märkt med en alkalisk fosfatas och komponenten (c) innehäller para-nitrofenylfosfat, 4-metylumbelliferyl eller 5-brom-4-klor-3-indolylfosfat.
9. Kitt enligt patentkrav 6, känneteck-n a t av att den monoklonala antikroppen i komponenten 20 (b) är märkt med beta-galaktosidas och komponenten (c) innehäller orto-nitrofenyl-beta-D-galaktopyranosid eller 4-metylumbelliferyl-beta-D-galaktopyranosid.
10. Kitt enligt patentkrav 6, känneteck-n a t av att den monoklonala antikroppen i komponenten 25 (b) är märkt med acetylkolinesteräs och komponenten (c) innehäller absolut acetyltiokolin och 5,5'-ditio-2-nitro-bensoesyra eller ett vattenlösligt sait av dessa.
11. Kitt enligt patentkrav 1, känneteck-n a t av att det lämpar sig för bestämning av vilken 30 eller vilka som heist ytantigener i humana blodpartiklar, säsom leukocyter, lymfocyter, T-lymfocyter, B-lymfocyter, granulocyter och trombocyter.
12. Kitt enligt patentkrav 11, känneteck-n a t av att det lämpar sig för bestämning av CD4- eller
13. Kitt enligt patentkrav 1, känneteck-n a t av att det lämpar sig för bestämning av vilken eller vilka som heist ytantigener i en patogen mikro-organism.
14. Kitt enligt patentkrav 13, känneteck- n a t av att den patogena mikroorganismen är Candida albicans.
15. Kitt enligt patentkrav 1, känneteck-n a t av att det lämpar sig för bestämning av vilken 10 eller vilka som heist membranantigener i tumörceller.
16. Kitt enligt patentkrav 15, känneteck-n a t av att tumörcellerna är urinvägscancerceller eller maligna hemopatiska celler.
17. Kitt enligt patentkrav 1 eller 2, k ä n n e - 15 tecknat av att komponenten (a) är en mikrotiter- platta, i vars häl en eller flera för en cellpopulations ytantigener specifikä monoklonala antikroppar är fästa, och komponenten (b) bestär av flera lösningar, av vilka var och en innehäller en monoklonal antikropp som är spe- 20 cifik för ytantigenen i en cellundergrupp, vilken yt-antigen är den viktigaste ytantigenen i den fästa cell-populationen.
18. Kitt enligt patentkrav 17, känneteck-n a t av att det lämpar sig för bestämning av för T-,
19. Kitt enligt patentkrav 17, känneteck-n a t av att det lämpar sig för karakterisering och bestämning av olika antigener, vilka utgör en ytantigen 30 epitop av maligna hemopatiska tumörceller.
20. Förfarande för immunologisk mätning av en för en cellpopulation eller dess undergrupp specifik ytantigen, kännetecknat av att förfarandet om-fattar: 35 a) immobilisering av cellpopulationen eller dess undergrupp, som innehäller antigenen som skall bestämmas, 95752 ρά en fast bärare genom användning av en eller flera mono-klonala antikroppar, som pä förhand fästs pä nämnda bärare medelst kovalent bindning eller fyslkallsk adsorption, ooh som känner igen cellpopulationens antigen, som inte är 5 samma som antigenen som skall bestämmas, ooh cellpopula-tionen eller dess undergrupp märks samtidigt med ätmin-stone en för antigenen som skall bestämmas specifik mono-klonal antikropp, som är märkt med ett radioisotop- eller enzymmärke, 10 b) uppföljning av inkubationstiden; c) tvättning av bäraren för att avlägsna obundna celler och överskottsantigen; d) tillsättning av en eller flera erforderliga rea-genser (substrat eller kromogen) för pävisning av enzymak- 15 tiviteten efter att antikroppen märkts med enzymet, e) avläsning av resultaten antingen genom radio-aktivitetsbestämning eller ljussignalmätning (färgbildning eller fluorescens) och eventuellt genom jämförelse med en standardrepresentant.
21. Bestämningsförfarande enligt patentkrav 20, kännetecknat av att den fasta bäraren är defi-nierad i patentkrav 1 eller 2.
22. Bestämningsförfarande enligt patentkrav 20 eller 21, kännetecknat av att den vid bestäm- 25 ningen använda monoklonala antikroppen inenhäller ett enzymmärke.
23. Bestämningsförfarande enligt patentkrav 22, kännetecknat av att det enzymatiska märket är peroxidas, och enzymaktiviteten mäts medelst oxiderat vat- 30 ten och en kromogen, som är orto-fenylendiamin, 2,2'-azi-. no-bis-(3-etylbensotiazolin-6-sulfon)syra, 3,3'-diamino- bensidin, 3-amino-9-etylkarbazol eller ett vattenlösligt sait av dessa.
24. Bestämningsförfarande enligt patentkrav 22, 35 kännetecknat av att det enzymatiska märket är en alkalisk fosfatas, och enzymaktiviteten mäts medelst 95752 para-nitrofenylfosfat, 4-metylumbelliferyl eller 5-brom- 4-klor-3-indolylfosfat.
25. Bestämningsförfarande enligt patentkrav 22, kännetecknat av att det enzymatiska märket är 5 beta-galaktosidas, och enzymaktiviteten mäts medelst orto-nitrofenyl-beta-D-galaktopyranosid eller 4-metylumbelliferyl -beta-D-galaktopyranosid.
25 T4-, T8- och B-lymfocyters undergrupper specifikä anti- gener.
26. Bestämningsförfarande enligt patentkrav 22, kännetecknat av att det enzymatiska märket är 10 acetylkolinesteräs, och enzymaktiviteten mäts medelst ace- tyltiokolin och som kromogen används 5,5'-ditio-2-nitro-bensoesyra eller ett vattenlösligt salt därav.
27. Bestämningsförfarande enligt patentkrav 20 eller 21, kännetecknat av att den vid bestäm- 15 ningen använda monoklonala antikroppen är märkt med en radioisotop, säsom jod-125 eller jod-131.
28. Förfarande enligt patentkrav 20, kännetecknat av att den eller de pä den fasta bäraren bundna monoklonala antikropparna är antikroppar mot HLA- 20 klass I.
29. Förfarande enligt patentkrav 20, kännetecknat av att det lämpar sig för bestämning av en eller flera ytantigener i humana blodpartiklar.
30. Förfarande enligt patentkrav 20, k ä n n e - . 25 tecknat av att de humana blodpartiklarna är leuko- cyter, lymfocyter, T-lymfocyter, T-lymfocyter som innehäl-ler en CD4-marker och kallas T4-lymfocyter, T-lymfocyter som innehäller en CD8-marker och kallas T8-lymfocyter, B-lymfocyter, granulocyter eller trombocyter. 30
31. Förfarande enligt patentkrav 20, känne- „ tecknat av att det lämpar sig för bestämning av vilken eller vilka som heist ytantigener i en patogen mik-roorganism.
32. Förfarande enligt patentkrav 31, känne- 35 tecknat av att den patogena mikroorganismen är Candida albicans. Il 95752
33. Förfarande enligt patentkrav 20, k ä n n e -tecknat av att det lämpar sig för bestämning av vilken eller vilka som heist membranantigener i tumör-celler. 5
34. Förfarande enligt patentkrav 33, k ä n n e - tecknat av att tumörcellerna är urinvägscancer-celler eller maligna hemopatiska celler.
35. Förfarande enligt patentkrav 20 eller 21, kännetecknat av att cellpopulationen immobi- 10 liseras pä en mikrotiterplatta med hjälp av en eller flera för denna populations ytantigen specifikä monoklonala antikroppar, och den fästa populationens undergrupp märks samtidigt direkt med flera lösningar, av vilka var och en innehäller en för ytantigenen hos undergruppen som skall 15 bestämmas specifik monoklonal antikropp.
35 CD8-antigener i dessa antigener innehällande humana T-lymfocyter, som kallas T4- eller T8-lymfocyter. 95752
36. Förfarande enligt patentkrav 35, känne tecknat av att det lämpar sig för bestämning av specifikä antigener för T-, T4-, T8- och B-lymfocyters undergrupper. 20
37. Förfarande enligt patentkrav 35, känne tecknat av att det kan användas för karakterisering och bestämning av olika antigener, som bildar en ytantigen epitop av maligna hemopatiska tumörceller. • 4 l l
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8713537 | 1987-09-30 | ||
| FR8713537A FR2621128B1 (fr) | 1987-09-30 | 1987-09-30 | Trousse et methode de dosage immunometrique applicables a des cellules entieres |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI884472A0 FI884472A0 (sv) | 1988-09-29 |
| FI884472L FI884472L (sv) | 1989-03-31 |
| FI95752B true FI95752B (sv) | 1995-11-30 |
| FI95752C FI95752C (sv) | 1996-03-11 |
Family
ID=9355391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI884472A FI95752C (sv) | 1987-09-30 | 1988-09-29 | Bestämningskitt och -förfarande för immunologisk mätning av hela celler |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0311492B1 (sv) |
| JP (1) | JPH01121755A (sv) |
| KR (1) | KR0126236B1 (sv) |
| AT (1) | ATE103711T1 (sv) |
| AU (1) | AU621310B2 (sv) |
| CA (1) | CA1340973C (sv) |
| DE (1) | DE3888779T2 (sv) |
| DK (1) | DK174032B1 (sv) |
| ES (1) | ES2053785T3 (sv) |
| FI (1) | FI95752C (sv) |
| FR (1) | FR2621128B1 (sv) |
| HK (1) | HK1001570A1 (sv) |
| IE (1) | IE63426B1 (sv) |
| IL (1) | IL87882A (sv) |
| NO (1) | NO177444C (sv) |
| PT (1) | PT88615B (sv) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200363406A1 (en) * | 2017-10-26 | 2020-11-19 | The University Of Houston System | Highly-specific assays |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5256532A (en) * | 1988-05-02 | 1993-10-26 | Zynaxis Technologies, Inc. | Methods, reagents and test kits for determination of subpopulations of biological entities |
| US5385822A (en) * | 1988-05-02 | 1995-01-31 | Zynaxis, Inc. | Methods for detection and quantification of cell subsets within subpopulations of a mixed cell population |
| US4953561A (en) * | 1989-09-18 | 1990-09-04 | Cancer Diagnostics, Inc. | Urine testing module and method of collecting urine antigen |
| US5795470A (en) * | 1991-03-25 | 1998-08-18 | Immunivest Corporation | Magnetic separation apparatus |
| US5466574A (en) * | 1991-03-25 | 1995-11-14 | Immunivest Corporation | Apparatus and methods for magnetic separation featuring external magnetic means |
| US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
| FR2684186B1 (fr) * | 1991-11-25 | 1994-02-25 | Pasteur Sanofi Diagnostics | Trousse pour le denombrement rapide des granulocytes, et procede utilisant ladite trousse. |
| TW378213B (en) * | 1992-11-04 | 2000-01-01 | Shionogy Seiyaku Kk | Basophil-binding monoclonal antibody, method for separation of basophils, method for chemical mediator released from basophils, and testing method for release of basophil-derived chemical mediators |
| US5374531A (en) * | 1993-03-22 | 1994-12-20 | Zynaxis, Inc. | Immunoassay for determination of cells |
| ES2066722B1 (es) * | 1993-05-20 | 1995-11-01 | Univ Pais Vasco | Procedimiento para el diagnostico de la candidiasis invasiva. |
| ATE186121T1 (de) | 1994-07-23 | 1999-11-15 | Roche Diagnostics Gmbh | Verfahren zur bestimmung des präthrombotischen status |
| US5658745A (en) * | 1995-02-17 | 1997-08-19 | E. I. Du Pont De Nemours And Company | Cell enumeration immunoassay |
| GB9912631D0 (en) * | 1999-05-28 | 1999-07-28 | Nat Blood Authority The | Cell counter |
| KR20020032751A (ko) * | 2000-10-27 | 2002-05-04 | 김희태 | 지지체로서 니트로셀룰로스 멤브레인을 사용한 마이크로웰 플레이트 단백질 칩 및 이의 제조 방법 |
| GB0129776D0 (en) * | 2001-12-13 | 2002-01-30 | Sec Dep For Environment Food & | Assay device and method |
| EP1599730A2 (en) * | 2003-03-03 | 2005-11-30 | Kouyama, Yoshihisa | Methods and apparatus for use in detection and quantitation of various cell types and use of optical bio-disc for performing same |
| JP5144950B2 (ja) * | 2007-03-29 | 2013-02-13 | 株式会社バイオマーカーサイエンス | ナチュラルキラー活性の評価方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0101724A1 (en) * | 1982-02-23 | 1984-03-07 | Ventrex Laboratories Inc. | Multipurpose supports for immunological and biological use |
| US4471056A (en) * | 1982-04-02 | 1984-09-11 | The Board Of Trustees Of The Leland Stanford Junior University | Method for HLA-DR typing of total human lymphocyte sample |
| US4606855A (en) * | 1982-07-26 | 1986-08-19 | Mex Research Associates C/O Leon Reimer | Monoclonal antibody to digoxin |
| US4503143A (en) * | 1982-08-20 | 1985-03-05 | Btc Diagnostics Limited Partnership | Enzyme immunoassay with two-part solution of tetramethylbenzidine as chromogen |
| US4591570A (en) * | 1983-02-02 | 1986-05-27 | Centocor, Inc. | Matrix of antibody-coated spots for determination of antigens |
| US4474892A (en) * | 1983-02-16 | 1984-10-02 | Board Of Trustees Of The Leland Stanford Junior University | Two-site immunoassays using monoclonal antibodies of different classes or subclasses and test kits for performing same |
| US4599304A (en) * | 1983-10-07 | 1986-07-08 | Becton, Dickinson And Company | Method for monitoring activated cell subpopulations |
| FR2571498B1 (fr) * | 1984-10-04 | 1988-04-08 | Immunotech Sa | Procede de separation de cellules utilisant des anticorps et des billes de faible densite |
| US4677061A (en) * | 1984-10-19 | 1987-06-30 | Genetic Systems Corporation | T-cell lymphocyte subset monitoring of immunologic disease |
| WO1986002733A1 (en) * | 1984-10-31 | 1986-05-09 | Alcon Laboratories, Incorporated | Sandwich immunoassay of antigens involved in ophthalmic disorders |
| US4661446A (en) * | 1985-02-19 | 1987-04-28 | Dana-Farber Cancer Institute, Inc. | Monoclonal antibodies and method of immunizing therewith |
| EP0204522A3 (en) * | 1985-05-30 | 1987-09-16 | Genetic Systems Corporation | Monoclonal antibody panel for histocompatibility typing |
| WO1986007633A1 (en) * | 1985-06-17 | 1986-12-31 | Electro-Nucleonics, Inc. | Test for determining false positive reactions in a testing procedure to detect the presence of antibody to microorganisms. |
| WO1987005398A1 (en) * | 1986-02-26 | 1987-09-11 | The University Of Melbourne | Hla-b27 testing |
| AU7357687A (en) * | 1986-04-29 | 1987-11-24 | Murex Corp. | Diagnostic kit for sexually transmitted diseases |
-
1987
- 1987-09-30 FR FR8713537A patent/FR2621128B1/fr not_active Expired - Fee Related
-
1988
- 1988-09-28 CA CA000578730A patent/CA1340973C/en not_active Expired - Fee Related
- 1988-09-28 PT PT88615A patent/PT88615B/pt not_active IP Right Cessation
- 1988-09-29 FI FI884472A patent/FI95752C/sv not_active IP Right Cessation
- 1988-09-29 IE IE293988A patent/IE63426B1/en not_active IP Right Cessation
- 1988-09-29 IL IL87882A patent/IL87882A/xx not_active IP Right Cessation
- 1988-09-29 NO NO884327A patent/NO177444C/no unknown
- 1988-09-29 AU AU22948/88A patent/AU621310B2/en not_active Ceased
- 1988-09-30 ES ES88402475T patent/ES2053785T3/es not_active Expired - Lifetime
- 1988-09-30 KR KR1019880012838A patent/KR0126236B1/ko not_active Expired - Fee Related
- 1988-09-30 AT AT88402475T patent/ATE103711T1/de not_active IP Right Cessation
- 1988-09-30 DE DE3888779T patent/DE3888779T2/de not_active Expired - Fee Related
- 1988-09-30 EP EP88402475A patent/EP0311492B1/fr not_active Expired - Lifetime
- 1988-09-30 DK DK198805502A patent/DK174032B1/da not_active IP Right Cessation
- 1988-09-30 JP JP63247289A patent/JPH01121755A/ja active Pending
-
1997
- 1997-11-26 HK HK97102252A patent/HK1001570A1/xx not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200363406A1 (en) * | 2017-10-26 | 2020-11-19 | The University Of Houston System | Highly-specific assays |
Also Published As
| Publication number | Publication date |
|---|---|
| IL87882A0 (en) | 1989-03-31 |
| DE3888779D1 (de) | 1994-05-05 |
| IE63426B1 (en) | 1995-04-19 |
| PT88615B (pt) | 1993-07-30 |
| AU621310B2 (en) | 1992-03-12 |
| FR2621128B1 (fr) | 1994-05-06 |
| CA1340973C (en) | 2000-04-25 |
| NO177444B (no) | 1995-06-06 |
| EP0311492A3 (en) | 1989-05-31 |
| FI884472A0 (sv) | 1988-09-29 |
| DK550288A (da) | 1989-03-31 |
| ATE103711T1 (de) | 1994-04-15 |
| EP0311492B1 (fr) | 1994-03-30 |
| EP0311492A2 (fr) | 1989-04-12 |
| KR0126236B1 (ko) | 1997-12-24 |
| NO884327L (no) | 1989-03-31 |
| JPH01121755A (ja) | 1989-05-15 |
| IE882939L (en) | 1989-03-30 |
| DK550288D0 (da) | 1988-09-30 |
| FR2621128A1 (fr) | 1989-03-31 |
| ES2053785T3 (es) | 1994-08-01 |
| FI884472L (sv) | 1989-03-31 |
| HK1001570A1 (en) | 1998-06-26 |
| DE3888779T2 (de) | 1994-09-08 |
| NO177444C (no) | 1995-09-13 |
| PT88615A (pt) | 1989-07-31 |
| AU2294888A (en) | 1989-04-06 |
| FI95752C (sv) | 1996-03-11 |
| KR890005518A (ko) | 1989-05-15 |
| IL87882A (en) | 1993-01-14 |
| DK174032B1 (da) | 2002-04-29 |
| NO884327D0 (no) | 1988-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI95752B (sv) | Bestämningskitt och -förfarande för immunologisk mätning av hela celler | |
| US5385822A (en) | Methods for detection and quantification of cell subsets within subpopulations of a mixed cell population | |
| US5122453A (en) | Method for discriminating surface stained lymphocytes | |
| US5374531A (en) | Immunoassay for determination of cells | |
| CA1104928A (en) | Oxidizing phenolic compounds in enzymatic immunoassay | |
| US5051356A (en) | Specific binding composition comprising a low pI protein or carbohydrate and a diagnostic test kit and method of use | |
| JP3330604B2 (ja) | 固相免疫学的検定法 | |
| JP3542808B2 (ja) | 細胞計数イムノアッセイ | |
| HK1001570B (en) | Kit and immunoassay method applicable to whole cells | |
| JP2732124B2 (ja) | 固相免疫検定用品及び該品を利用した検定法 | |
| US6461825B1 (en) | Immunometric assay kit and method applicable to whole cells | |
| US5047318A (en) | Imidazole leuco dye composition containing 4'-hydroxyacetanilide, diagnostic kit and method using same | |
| FI96723C (sv) | Testförpackning för bestämning av entsymer och bestämningsförfarande | |
| EP0217845B1 (fr) | Procede de determination immunologique d'une substance biologique dans un echantillon | |
| CA1254134A (en) | Specific binding flow cytometry method | |
| JPH0792460B2 (ja) | 抽出組成物として界面活性剤混合物を使用する歯周病に随伴する微生物検出用キットおよびその検出方法 | |
| CA2028175A1 (en) | Buffered wash composition, insolubilizing composition, test kits and method of use | |
| JPH05346428A (ja) | 顆粒球の迅速なカウントのためのキット及び前記キットを使用する方法 | |
| JP2892814B2 (ja) | 抗結核菌抗体様物質の測定法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| MM | Patent lapsed |
Owner name: SANOFI-SYNTHELABO |